New painkiller may cut opioid use after breast reduction
NCT ID NCT05891613
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested two different painkillers in 32 women having breast reduction surgery. Each woman received a long-acting painkiller (liposomal bupivacaine) on one breast and a standard painkiller (bupivacaine hydrochloride) on the other. The goal was to see which one provided better pain relief and reduced the need for opioid painkillers in the first three days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Liposomal bupivacaine (Exparel) and bupivacaine hydrochloride
- What this could lead to
- If it works, this could point toward a better way to manage pain after breast reduction, possibly reducing the need for opioids.
- What could go wrong
- This is a small, single-blind, non-randomized trial with only 32 participants, so results may not apply to everyone. The benefit may be small or not clinically meaningful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST REDUCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.